Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of encorafenib + cetuximab + pembrolizumab versus pembrolizumab in metastatic colorectal cancer
2021-003715-26Phase 2Active
- Sponsor
- Pfizer
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib, cetuximab and pembrolizumab in colorectal cancer (CRC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival per investigator. Started Mar 2022; status: active.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2021-003715-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003715-26.